Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment with Gefitinib or Erlotinib in EGFR+ NSCLC
NCT03382795Phase 2Unknown
- Sponsor
- Korea University Guro Hospital
- Start
- Jan 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib, erlotinib in non-small cell lung cancer (NSCLC), sponsored by Korea University Guro Hospital. Status: unknown.
02
Drugs
gefitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03382795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382795.